ESC 2025

29 August – 1 September 2025 in Madrid, Spain
Find all information about Impella® heart pumps at ESC 2025 here.

We Are Looking Forward to Meeting You at ESC 2025

Discover our scientific program at ESC 2025 in Madrid and learn more about Impella® devices and pMCS. We are looking forward to welcoming you at our booth and in our scientific sessions. Get informed now about this year's conference highlights.

Shaping the Future of Heart Recovery

  • 390,000+

    Patients have been treated with Impella® heart pumps

  • 1,500+

    Peer-reviewed publications for High-Risk PCI and Cardiogenic Shock

  • 24/7

    Abiomed Collaborative Care Clinical Support

  • 17

    Clinical Guidelines and Consensus Statements covering Impella heart pumps

People listening to a presentation People listening to a presentation

Visit our Tutorial

Life in the Post DanGer Shock Era: Optimizing Guideline-Driven Care

Date and Time:

  • Friday, 29th August 2025 | 11:00–12:00, 13:30–14:30, 15:30–16:30
  • Saturday, 30th August 2025 | 11:00–12:00, 13:30–14:30, 15:30–16:30
  • Sunday, 31st August 2025 | 11:00–12:00, 13:30–14:30, 15:30–16:30

Location:

IFEMA Madrid | Hall 8 Exhibition East | Tutorial Room E11

 

Save the Date!

Meet Dr. Jacob Møller — Principal Investigator of the DanGer Shock RCT at our Tutorial

  • Friday at 11:30
  • Saturday at 15:30

Location:
IFEMA Madrid | Hall 8 Exhibition East | Tutorial Room E11

 

DanGer Shock Randomized Controlled Trial (RCT) Confirms Routine Use of Impella® Heart Pumps Improve Survival in Heart Attack with Shock1

This investigator-initiated study is the first positive RCT of Impella in CS, assessed the mortality rates between groups with and without Impella CP® usage in treating patients with AMI-CS due to STEMI, undergoing emergency PCI.

Recommendations for MCS in Patients with ACS and Cardiogenic Shock

The updated Acute Coronary Syndrome (ACS) guidelines now recommend microaxial intravascular flow pumps (mAFP), such as Impella® as a Class 2a option for patients with STEMI and severe or refractory cardiogenic shock. In contrast, intra-aortic balloon pump (IABP) and venoarterial extracorporeal membrane oxygenation (VA-ECMO) have been downgraded to Class 3 due to no shown benefit.2

Download the Pocket Guide for Cardiogenic Shock and Escalation

REFERENCES

  1. Møller J, et al. (2024). Microaxial Flow Pump or Standard Care in Infarct-Related CS. N Engl J Med. DOI: 10.1056/NEJMoa2312572
  2. Rao, SV, et al. (2025). ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. https://pubmed.ncbi.nlm.nih.gov/40013746/ 

Sign up for latest updates

NPS-3046

This information is intended for use by customers, patients, and healthcare professionals in [region] only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside [region], and the information from other sites you visit may not be appropriate for use in [region].